SMN1 and cholangiocarcinoma: SMA is the most well-accepted CAF marker, and high expression of SMA has been reported to be associated with poor survival in several gastrointestinal cancers, including hepatocellular carcinoma [36], pancreatic cancer [34], and cholangiocarcinoma [37].